| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1049316983 |
| P356 | DOI | 10.1385/MO:23:4:431 |
| P698 | PubMed publication ID | 17303901 |
| P50 | author | Magne Børset | Q39185277 |
| P2093 | author name string | Øyvind Hjertner | |
| Anders Waage | |||
| Anders Sundan | |||
| Therese Standal | |||
| P2860 | cites work | Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation | Q24311588 |
| Osteoprotegerin: a novel secreted protein involved in the regulation of bone density | Q24313918 | ||
| RANK is essential for osteoclast and lymph node development | Q24598872 | ||
| Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand | Q24653311 | ||
| Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL | Q24682139 | ||
| Disabling of receptor activator of nuclear factor-kappaB (RANK) receptor complex by novel osteoprotegerin-like peptidomimetics restores bone loss in vivo | Q28191731 | ||
| High bone density due to a mutation in LDL-receptor-related protein 5 | Q28217891 | ||
| The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma | Q28236113 | ||
| Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation | Q28240596 | ||
| RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis | Q28293009 | ||
| Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase | Q28378368 | ||
| The Wnt antagonist secreted frizzled-related protein-1 is a negative regulator of trabecular bone formation in adult mice | Q28508070 | ||
| OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis | Q28589430 | ||
| Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor | Q28590950 | ||
| Osteoclast differentiation and activation | Q29547556 | ||
| Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts | Q29547605 | ||
| Caught up in a Wnt storm: Wnt signaling in cancer | Q29617494 | ||
| Bone morphogenetic proteins: multifunctional regulators of vertebrate development | Q29618986 | ||
| Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand | Q29619331 | ||
| Glucocorticoid decreases circulating osteoprotegerin (OPG): possible mechanism for glucocorticoid induced osteoporosis | Q32135517 | ||
| The pharmacology of bisphosphonates and new insights into their mechanisms of action | Q33746152 | ||
| The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. | Q33823576 | ||
| Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression | Q33944735 | ||
| Gene expression profiling of multiple myeloma reveals molecular portraits in relation to the pathogenesis of the disease | Q34182154 | ||
| Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma | Q34225092 | ||
| Myeloma bone disease | Q34326545 | ||
| Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. | Q34469691 | ||
| Role of RANK ligand in mediating increased bone resorption in early postmenopausal women | Q34912769 | ||
| Bone morphogenetic proteins, their antagonists, and the skeleton | Q35109618 | ||
| HMG CoA reductase inhibitors and the skeleton: a comprehensive review | Q35123607 | ||
| Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression | Q35169193 | ||
| The ins and outs of Wingless signaling. | Q35631939 | ||
| Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. | Q35848843 | ||
| In vitro growth of human multiple myeloma: implications for biology and therapy | Q36097631 | ||
| The critical role of interleukin-6, interleukin-1B and macrophage colony-stimulating factor in the pathogenesis of bone lesions in multiple myeloma | Q36137659 | ||
| Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone destruction in a model of myeloma bone disease | Q36169814 | ||
| Osteoclast differentiation independent of the TRANCE-RANK-TRAF6 axis | Q36402845 | ||
| RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism | Q37108966 | ||
| Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation | Q38325516 | ||
| Human myeloma cells adhere to fibronectin in response to hepatocyte growth factor | Q40436931 | ||
| A selective c-met inhibitor blocks an autocrine hepatocyte growth factor growth loop in ANBL-6 cells and prevents migration and adhesion of myeloma cells | Q40505746 | ||
| The HMG-CoA reductase inhibitor simvastatin overcomes cell adhesion-mediated drug resistance in multiple myeloma by geranylgeranylation of Rho protein and activation of Rho kinase | Q40552228 | ||
| Anti-alpha4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis | Q40557146 | ||
| Bone morphogenetic protein-5, -6 and -7 inhibit growth and induce apoptosis in human myeloma cells | Q40604725 | ||
| IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells | Q40616669 | ||
| Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and alpha(4)beta(1)-integrin enhances production of osteoclast-stimulating activity. | Q40858675 | ||
| Stimulation of bone formation in vitro and in rodents by statins | Q40914337 | ||
| Hepatocyte growth factor (HGF) induces interleukin-11 secretion from osteoblasts: a possible role for HGF in myeloma-associated osteolytic bone disease. | Q40916337 | ||
| Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis | Q40926683 | ||
| Marked osteoblastopenia and reduced bone formation in a model of multiple myeloma bone disease in severe combined immunodeficiency mice | Q40975330 | ||
| The HIV protease inhibitor ritonavir blocks osteoclastogenesis and function by impairing RANKL-induced signaling | Q41062466 | ||
| Adhesion molecules involved in the binding of murine myeloma cells to bone marrow stromal elements | Q41260107 | ||
| Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. | Q42543174 | ||
| Serum syndecan-1, basic fibroblast growth factor and osteoprotegerin in myeloma patients at diagnosis and during the course of the disease | Q43540466 | ||
| Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index | Q44032751 | ||
| Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease. | Q44291805 | ||
| A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases | Q44291815 | ||
| How myeloma cells escape bisphosphonate-mediated killing: development of specific resistance with preserved sensitivity to conventional chemotherapeutics | Q44503958 | ||
| Inhibition of protein geranylgeranylation induces apoptosis in myeloma plasma cells by reducing Mcl-1 protein levels | Q44509632 | ||
| Zoledronic Acid Treatment Results in Retention of Femoral Head Structure After Traumatic Osteonecrosis in Young Wistar Rats | Q44647823 | ||
| Novel and selective small molecule stimulators of osteoprotegerin expression inhibit bone resorption | Q44725393 | ||
| Design of potent, selective, and orally bioavailable inhibitors of cysteine protease cathepsin k. | Q44736860 | ||
| Nonpeptide alphavbeta3 antagonists. Part 11: discovery and preclinical evaluation of potent alphavbeta3 antagonists for the prevention and treatment of osteoporosis | Q45060201 | ||
| Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. | Q45713487 | ||
| A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women | Q46133598 | ||
| Bisphosphonates stimulate formation of osteoblast precursors and mineralized nodules in murine and human bone marrow cultures in vitro and promote early osteoblastogenesis in young and aged mice in vivo | Q46291792 | ||
| Selective inhibition of NF-kappa B blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo | Q47446256 | ||
| Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease | Q48022318 | ||
| Stimulation of osteoprotegerin production is responsible for osteosclerosis in mice overexpressing TPO. | Q52548768 | ||
| Expression of receptor activator of nuclear factor kappaB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma. | Q52952110 | ||
| Evidence for the secretion of an osteoclast stimulating factor in myeloma. | Q53791263 | ||
| Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells | Q56453539 | ||
| Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease | Q57374932 | ||
| Bisphosphonates in multiple myeloma | Q57692401 | ||
| T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-γ | Q59064307 | ||
| Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease | Q62003041 | ||
| Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption | Q67602665 | ||
| Production of interleukin-1 by bone marrow myeloma cells | Q69519942 | ||
| Quantitative histology of myeloma-induced bone changes | Q70506066 | ||
| Hepatocyte growth factor and its receptor c-met in multiple myeloma | Q71775751 | ||
| Lack of IL-1 secretion from human myeloma cells highly purified by immunomagnetic separation | Q72311470 | ||
| Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment | Q73321910 | ||
| Serum syndecan-1: a new independent prognostic marker in multiple myeloma | Q73337882 | ||
| Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma | Q73971509 | ||
| Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma. The Nordic Myeloma Study Group | Q74106121 | ||
| Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma | Q74676116 | ||
| Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment | Q77337113 | ||
| The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway | Q77669992 | ||
| Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma | Q78835000 | ||
| Serum levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) correlate with the extent of bone disease and survival in patients with multiple myeloma | Q79084045 | ||
| P433 | issue | 4 | |
| P921 | main subject | bone disease | Q4941552 |
| P304 | page(s) | 431-441 | |
| P577 | publication date | 2006-01-01 | |
| P1433 | published in | Medical Oncology | Q2152666 |
| P1476 | title | Bone disease in multiple myeloma | |
| P478 | volume | 23 |
| Q37197900 | BCL-B (BCL2L10) is overexpressed in patients suffering from multiple myeloma (MM) and drives an MM-like disease in transgenic mice | cites work | P2860 |
Search more.